Top Markets
#1 Akedo Akedo +59.31%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.07%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.55%
#6 Ο„emplar Ο„emplar +26.67%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.66%
#8 Bitway Bitway +18.26%
#9 Perle Perle +16.48%
#10 Cap Cap +16.47%
Coin of the day
Akedo Akedo
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Peringkat dalam Saham #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Harga Saham
$0.41
Terakhir disinkronkan: 2025-01-23
Kapitalisasi Pasar
$1.08M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan CohBar, Inc. (CWBR)

Kategori

Healthcare
Rasio P/B untuk CohBar, Inc. (CWBR)
Rasio P/B per August 2026 TTM: 0.08
Menurut laporan keuangan dan harga saham terbaru dari CohBar, Inc., rasio P/B saat ini (TTM) adalah 0.08. Pada akhir 2021, rasio P/B perusahaan adalah 0.91.
Riwayat rasio P/B untuk CohBar, Inc. dari 2011 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) 0.08 -75.78%
2022 0.32 -64.70%
2021 0.91 -74.27%
2020 3.54 -57.97%
2019 8.42 17.87%
2018 7.14 -70.78%
2017 24.44 213.13%
2016 7.81 115.36%
2015 3.62 -84.35%
2014 23.15 -103.81%
2013 -607.96 -3,077.68%
2012 20.42 0.00%
2011 0.00 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 7,979.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 8,091.35%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 4,589.03%
BE